SF 4113
Introduction - 94th Legislature (2025 - 2026)
Posted on 03/05/2026 09:29 a.m.
1.6 1.7 1.8 1.9 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 2.24 2.25 2.26 2.27 2.28 2.29 2.30 2.31 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 3.20 3.21 3.22 3.23 3.24 3.25 3.26 3.27 3.28 3.29 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 4.19 4.20 4.21 4.22 4.23 4.24 4.25 4.26 4.27 4.28 4.29 4.30 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 5.9 5.10 5.11 5.12 5.13 5.14 5.15 5.16 5.17 5.18 5.19 5.20 5.21 5.22 5.23 5.24
5.25
5.26 5.27 5.28 5.29 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8
6.9
A bill for an act
relating to health; establishing the Minnesota Parkinson's Research Trust Fund;
requiring a report; appropriating money; proposing coding for new law in Minnesota
Statutes, chapter 144.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
Section 1.
new text begin
[144.0531] MINNESOTA PARKINSON'S RESEARCH TRUST FUND.
new text end
new text begin Subdivision 1. new text end
new text begin Short title. new text end
new text begin
This section may be cited as the "Minnesota Parkinson's
Research Trust Fund Act."
new text end
new text begin Subd. 2. new text end
new text begin Purpose and findings. new text end
new text begin
The legislature finds:
new text end
new text begin
(1) Parkinson's disease is a progressive neurological disorder affecting approximately
one million Americans, with an estimated 90,000 new diagnoses each year;
new text end
new text begin
(2) the financial burden of Parkinson's disease on individuals, families, and the health
care system is immense, with annual costs in the United States exceeding $52,000,000,000,
including medical expenses and lost income;
new text end
new text begin
(3) there is currently no cure for Parkinson's disease, and innovative research is essential
to advance therapies, improve patient outcomes, and alleviate the burden of Parkinson's
disease; and
new text end
new text begin
(4) caregivers of individuals with Parkinson's disease provide critical support, often at
significant personal and financial sacrifice.
new text end
new text begin Subd. 3. new text end
new text begin Establishment of the fund. new text end
new text begin
The Minnesota Parkinson's Research Trust Fund
is established in the state treasury. The trust fund is a special revenue fund and is not part
of the general fund. Money in the trust fund is held in trust and may be expended only as
provided in this section. The trust fund shall be used to support innovative research on
Parkinson's disease and provide caregiver assistance as provided in this section.
new text end
new text begin Subd. 4. new text end
new text begin Purposes. new text end
new text begin
The Minnesota Parkinson's Research Trust Fund is established to:
new text end
new text begin
(1) create and expedite innovation in research on Parkinson's disease and related disorders
to: (i) improve the health of residents of Minnesota; (ii) enhance the potential for a medical
or scientific breakthrough in research on Parkinson's disease and related disorders; and (iii)
enhance the research superiority of Minnesota regarding Parkinson's disease and related
disorders;
new text end
new text begin
(2) attract scientific researchers and create exceptional jobs in Minnesota; and
new text end
new text begin
(3) develop and implement a research plan to foster synergistic collaboration between
eligible institutions of higher education, institutional partners, and other grant recipients for
research on Parkinson's disease and related disorders.
new text end
new text begin Subd. 5. new text end
new text begin Powers and duties. new text end
new text begin
(a) The commissioner:
new text end
new text begin
(1) may award grants to institutions of learning, advanced medical research facilities,
public or private persons, and collaboratives in Minnesota that are involved in Parkinson's
research that furthers the purposes of this section, including:
new text end
new text begin
(i) implementation of a research plan;
new text end
new text begin
(ii) research, including translational and clinical research, into the causes of, means of
prevention of, and treatment and rehabilitation for Parkinson's disease and related disorders;
new text end
new text begin
(iii) research, including translational research, to develop therapies, protocols, medical
pharmaceuticals, or procedures for the substantial mitigation of the symptoms of Parkinson's
disease and related disorders;
new text end
new text begin
(iv) facilities, equipment, supplies, salaries, benefits, and other costs related to the
research of Parkinson's disease and related disorders; and
new text end
new text begin
(v) prevention programs and strategies to mitigate the detrimental health impacts of
Parkinson's disease and related disorders;
new text end
new text begin
(2) shall collaborate with relevant state agencies, coordinating councils, and consortiums
to enhance health care and research for Parkinson's disease and related disorders;
new text end
new text begin
(3) shall establish the appropriate standards and oversight bodies to ensure grant money
is used for the purposes of this section;
new text end
new text begin
(4) shall employ necessary staff to administer the trust fund;
new text end
new text begin
(5) shall manage grant accounting, grant monitoring, technical and document management
of the grant application review process, legal services, and compliance services;
new text end
new text begin
(6) shall monitor grant contracts authorized by this section and ensure each grant recipient
complies with the terms and conditions of the contract;
new text end
new text begin
(7) shall ensure all grant proposals comply with this section and rules adopted under
this chapter before the proposals are submitted to the oversight committee for approval;
new text end
new text begin
(8) shall monitor grant proposals for conflicts of interest; and
new text end
new text begin
(9) shall collaborate with the statewide research and clinical data registry for research
related to Parkinson's disease and related disorders.
new text end
new text begin
(b) The commissioner shall implement, monitor, and, as necessary, revise the research
plan.
new text end
new text begin Subd. 6. new text end
new text begin Administration and oversight. new text end
new text begin
(a) The commissioner of health shall establish
a Neurodegenerative Disease Advisory Council to oversee the administration of the trust
fund. The advisory council shall consist of representatives from:
new text end
new text begin
(1) leading research institutions in Minnesota;
new text end
new text begin
(2) Parkinson's advocacy organizations;
new text end
new text begin
(3) caregiver support groups; and
new text end
new text begin
(4) the medical community specializing in neurological diseases.
new text end
new text begin
(b) The advisory council shall establish guidelines for grant applications, selection
criteria, and reporting requirements to ensure transparency and accountability.
new text end
new text begin Subd. 7. new text end
new text begin Reporting requirements. new text end
new text begin
Recipients of grant funds shall submit an annual
report to the commissioner detailing:
new text end
new text begin
(1) the progress of funded research;
new text end
new text begin
(2) outcomes and measurable impacts of caregiver support programs; and
new text end
new text begin
(3) any additional recommendations for improving the program's effectiveness.
new text end
new text begin Subd. 8. new text end
new text begin Annual report. new text end
new text begin
(a) No later than January 31 of each year, the commissioner
shall prepare and submit to the chairs and ranking minority members of the legislative
committees with primary jurisdiction over health finance a report on:
new text end
new text begin
(1) the trust fund's grants under this section;
new text end
new text begin
(2) a list of recipients of grants awarded during the preceding state fiscal year and the
grant amount awarded to each recipient;
new text end
new text begin
(3) any research accomplishments a grant recipient or the recipient's partners achieved
during the preceding state fiscal year;
new text end
new text begin
(4) an assessment of the progress of grant recipients;
new text end
new text begin
(5) a statement of strategic research plans;
new text end
new text begin
(6) an estimate of the financial cost to Minnesota of Parkinson's disease and related
disorders during the most recent state fiscal year for which data is available, including the
amounts Minnesota spent related to Parkinson's disease and related disorders under Medicaid,
the Teacher Retirement System of Minnesota, and the Employees Retirement System of
Minnesota; and
new text end
new text begin
(7) a statement of grant's compliance program activities, including any recommendations
identified through the activities.
new text end
new text begin
(b) The commissioner must publish the report on the department's website.
new text end
new text begin Subd. 9. new text end
new text begin State plan to address neurodegenerative diseases. new text end
new text begin
(a) Within 12 months of
the effective date of this act, the commissioner, with input from the council and stakeholders,
shall develop and publish a state plan to address neurodegenerative diseases.
new text end
new text begin
(b) At a minimum, the plan shall include:
new text end
new text begin
(1) current estimates of prevalence, incidence, and demographic distribution for each
condition and identification of data gaps;
new text end
new text begin
(2) a determination of objectives that include prevention, diagnosis, care, research,
surveillance, workforce, and support services;
new text end
new text begin
(3) strategies for improving early diagnosis and timely access to specialists;
new text end
new text begin
(4) care coordination and caregiver support strategies;
new text end
new text begin
(5) a workforce development plan, including training for neurologists, primary care
clinicians, allied health professionals, and long-term care staff;
new text end
new text begin
(6) a public awareness and education plan emphasizing equity and culturally competent
outreach;
new text end
new text begin
(7) a data and registry integration strategy, including mechanisms for secure data sharing
and research access;
new text end
new text begin
(8) a research and innovation agenda with prioritized areas for translational and clinical
research;
new text end
new text begin
(9) recommendations for sustainable financing, including public and private funding
streams and potential creation of a dedicated research or program fund; and
new text end
new text begin
(10) evaluation metrics and a schedule for monitoring, reporting, and planning updates
at least every five years.
new text end
new text begin
(c) The draft plan shall be made available for public comment for at least 30 days before
finalization.
new text end
new text begin Subd. 10. new text end
new text begin Coordination of activities. new text end
new text begin
(a) The commissioner shall coordinate activities
under this section with relevant federal agencies, federally supported research centers,
academic medical centers, and private sector partners to leverage resources and avoid
duplication.
new text end
new text begin
(b) To the extent permitted by law, the commissioner may enter into memoranda of
understanding to facilitate data sharing and collaborative research.
new text end
new text begin Subd. 11. new text end
new text begin Protections and limitations. new text end
new text begin
(a) Nothing in this section shall be construed to
require insurance coverage beyond what is otherwise required by state or federal law.
new text end
new text begin
(b) Participation in the registry is voluntary, and no person shall be denied services or
benefits for refusing to enroll.
new text end
new text begin
(c) Data collected under this section shall not be used for nonresearch law enforcement
or discriminatory purposes.
new text end
new text begin Subd. 12. new text end
new text begin Rulemaking authority. new text end
new text begin
The commissioner may adopt rules or regulations
necessary to implement this section.
new text end
new text begin Subd. 13. new text end
new text begin Severability. new text end
new text begin
If any provision or application of this section is held invalid,
the remainder shall continue in effect.
new text end
new text begin EFFECTIVE DATE. new text end
new text begin
This section is effective October 1, 2026.
new text end
Sec. 2. new text begin APPROPRIATION AND ALLOCATION OF FUNDS.
new text end
new text begin
(a) $25,000,000 in fiscal year 2027 is appropriated from the general fund to the
commissioner of health to implement Minnesota Statutes, section 144.0531.
new text end
new text begin
(b) Of the amount in paragraph (a):
new text end
new text begin
(1) $20,000,000 shall be awarded through competitive grants to state universities, research
institutions, and medical centers actively engaged in Parkinson's research with priority given
to innovative therapies and projects aimed at finding a cure;
new text end
new text begin
(2) $3,000,000 shall be used to establish and expand programs that support caregivers
of individuals living with Parkinson's disease, including respite care, training, and mental
health resources; and
new text end
new text begin
(3) $2,000,000 shall be used to establish a Neurodegenerative Disease Advisory Council
that shall develop and publish a state plan to address neurodegenerative diseases.
new text end
new text begin EFFECTIVE DATE. new text end
new text begin
This section is effective July 1, 2026.
new text end